4basebio AG: 4basebio AG resolves on capital reduction by way of redemption of approx. 5.2 million treasury shares in accordance with the authorizing resolution of the general meeting
4basebio AG / Key word(s): Corporate Action
4basebio AG resolves on capital reduction by way of redemption of approx. 5.2 million treasury shares in accordance with the authorizing resolution of the general meeting
Heidelberg, Germany, and Cambridge, UK, 20 April 2020 - The management board of 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) has decided today, based on the authorization of the general meeting of 19 December 2019 and with the approval of the supervisory board, to reduce the share capital of the Company by EUR 5,230,667.00 by way of redemption of 5,230,667 treasury shares (approx. 10 % of the share capital of the Company).
The redemption will come into effect at the time of the registration of the capital reduction with the commercial register. Each no-par value share will still represent an arithmetic proportion of the share capital of the Company of EUR 1.00. Upon such redemption the Company will not hold any treasury shares anymore.
*** end of ad hoc announcement ***Contact:
David Roth, CFO
Waldhofer Str. 102
69123 Heidelberg, GERMANY
Tel. +49 6221 3540 125
Fax. +49 6221 3540 127
20-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Waldhofer Str. 102|
|Phone:||+49 (0) 6221 3540 125|
|Fax:||+49 (0) 6221 3540 127|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1025247|
|End of Announcement||DGAP News Service|